← Oncology Approval Tracker

FDA DECISION ·

Brukinsa tablets

zanubrutinib · BeOne Medicines USA

Accelerated approvalNew formulationMarginal zone lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

A 160 mg tablet formulation for adults with relapsed or refractory marginal zone lymphoma after at least one regimen containing an anti-CD20 therapy.

LAMPGEN ANALYSIS

Why it matters

This formulation action retains accelerated status for the prior anti-CD20-treated marginal zone lymphoma population.

What research teams should watch

Verify exposure to an anti-CD20 agent rather than recording only the overall number of prior lines.

PRIMARY RECORDS

Sources